Skip to ContentSkip to Navigation
About us Latest news News News articles

Genetics of clear cell renal carcinoma: new tumor suppressor genes and aberrant chromatin regulation

07 December 2011

PhD ceremony: Mr. G. Duns, 14.30 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Dissertation: Genetics of clear cell renal carcinoma: new tumor suppressor genes and aberrant chromatin regulation

Promotor(s): prof. R.M.W. Hofstra

Faculty: Medical Sciences

Clear cell renal cell carcinoma (ccRCC) is genomically characterized by the frequent loss of the short arm of chromosome 3 (3p), suggesting the presence of tumor suppressor genes (TSGs) in this genomic region. This thesis presents the search for these TSGs. Using a method called GINI, we identified inactivating mutations in histone methyltransferase gene SETD2, located at 3p21, in several ccRCC samples. SETD2 trimethylates histone 3 at position K36, a modification which has been suggested to be involved in alternative splicing. SETD2 knockdown in renal cells indeed resulted in an apparent change in alternative splicing for a set of genes, several of which are interesting with respect to tumorigenic development. Targeted exome sequencing of ten primary ccRCC tumors revealed inactivating mutations in the known ccRCC tumor suppressor gene VHL, but also in PBRM1, and BAP1 in six, seven, and one of these tumors, respectively. PBRM1 and BAP1 are both located at 3p21 and code for the chromatin targeting subunit of the SWI/SNF chromatin-remodeling complex and an enzyme involved in histone deubiquitination, respectively. Sequencing of PBRM1 in ccRCC-derived cell lines confirmed its frequent inactivation in ccRCC, suggesting that this is a major TSG for ccRCC. Thus, 3p harbors several genes that do contribute to ccRCC development. Several of these genes encode proteins that modify histone tails or remodel chromatin, suggesting that aberrant chromatin regulation is a core driver event in the development of ccRCC.

Last modified:13 March 2020 01.09 a.m.
View this page in: Nederlands

More news

  • 27 August 2024

    UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling

    Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...

  • 17 July 2024

    Veni-grants for ten researchers

    The Dutch Research Council (NWO) has awarded a Veni grant of up to €320,000 each to ten researchers of the University of Groningen and the UMCG. The Veni grants are designed for outstanding researchers who have recently gained a PhD.

  • 16 July 2024

    Medicine still subjects to male bias

    Aranka Ballering studied the course of illness in people with common symptoms. One of the most striking findings to emerge from her research was that on average, women have a different – and less extensive – course of illness than men.